In renal cell carcinoma, RRM2 silencing enhances the antitumor activity of PD-L1 blockade and sunitinib, likely by modulating immune evasion pathways (Xiong et al. 2021). Here, RRM2 is linked to hereditary clear cell renal cell carcinoma.